Medibank (ASX:MPL) share price slips as customers hit 3.7 million

What's moving the Medibank share price today?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medibank Private Ltd (ASX: MPL) share price is moving higher this morning. This follows the release of the private health insurers' annual report for 2021.

While the financial results had already been shared with investors back on 25 August 2021, today's release comes with some added details and commentary.

At the time of writing, the Medibank Private share price is down 0.28% to $3.55 in early trade.

Let's dive into the report.

A man sitting at his dining table looks at his laptop and ponders the share price.

Image source: Getty Images

More customers getting more back

To kick things off, the report opens with an elating one-liner, stating "We grew more in the past 12 months than we have in over 10 years." Such a statement could have investors jumping for joy.

Although the exact metric being measured isn't specified, we know that it's not pertaining to the company's net earnings after tax. In FY21, Medibank's group net profit after tax increased 39.8% to $441.2 million. We only need to go back to FY16 to see earnings grow more than this. For reference, FY16 witnessed the bottom line climb 46% to $417.6 million.

Additionally, customer numbers across the Medibank and ahm brands have slipped since 2016 as well. According to its annual report at the time, the company served 3.8 million customers. Meanwhile, the company counts 3.7 million people as customers — a reduction of nearly 3%. This might be weighing on the Medibank Private share price this morning.

However, what has increased is the amount of money paid in claims to customers. For the recent financial year, Medibank coughed up $5.6 billion in claims, increasing 2% from the prior year. In fact, the company's COVID financial support package for customers was the largest in its 45-year history.

To date, Medibank has provided $300 million, with $103 million in COVID permanent net claims savings being returned in premium relief. Adding to this, CEO David Koczkar said, "We stand by our commitment not to profit from COVID and will continue to return any related permanent net claims savings to our customers."

This act of returning some of the premiums paid by customers was in recognition of the impact COVID has had on people's ability to use their health insurance.

It appears premium return helped bolster the company's brand among customers. In the year, Medibank customer advocacy rose 5.3 points to 37.1. Likewise, ahm gained 1.8 points to finish at 43.

Medibank share price wobbles on directors retirement

In addition to the annual report, Medibank also announced the retirement of two non-executive directors of its board.

According to the release, non-exec directors Christine O'Reilly and Peter Hodgett will retire from the board on 18 November 2021. This will be at the conclusion of the annual general meeting, of which, the directors have opted not to stand for re-election.

Commenting on the news, Medibank chair Mike Wilkins said:

I would like to take this opportunity to thank both Christine and Peter for their valuable contribution to our
company during their time as directors. They both joined the Board prior to Medibank's listing on the
Australian Securities Exchange and helped guide the business through its transition from government-owned business to privatised company.

The search for two new directors is already underway.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Woman flexes muscles after donating blood.
Healthcare Shares

CSL shares: 1 number that investors shouldn't ignore

This one number has me rethinking a CSL investment.

Read more »

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

CSL shares rebound 79% from multi-year low: Here's what brokers tip next

The ASX biotech company announced its FY26 results yesterday.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months

Find out what brokers tip for this ASX healthcare stock next.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Earnings Results

Healius posts FY26 revenue growth, narrows underlying loss

Its underlying loss narrowed, but its reported loss after tax widened to $415.6 million.

Read more »

patient with doctor, medical company, medical insurance
Healthcare Shares

CSL shares just had their best day in 20 years. What did I just miss?

A US$2.6 billion loss sent CSL shares soaring. Here is why.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

EBOS FY26 earnings: profit edges higher, dividend steady

EBOS Group posts a rise in FY26 profit and revenue as it maintains its final dividend for shareholders.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Bell Potter tips more than 140% upside for this out of favour ASX biotech

This company has made good progress over the past quarter.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »